Supplementary Figure S1.pdf (258.64 kB)

Supplementary Figure S1: Bioanalyzer Results obtained from PDAC compartments.(A) Human brain total RNA Was obtained from ThermoFisher nd diluted to 625pg/μl (left) and 312. 5pg/μl (right), Which was the expected range for total RNA Recovery from PDAC Compartments. Small RNA And ribosomal RNA Peaks are indicated. Total RNA Recovery from tumor (B), Stroma (C), And microvasculature (D). Recovery Was highest from 271, 100Μm 2 Tumor compartment compared to stroma and microvasculature.Supplementary data

Download (258.64 kB)
dataset
posted on 17.10.2019 by Susanna Skalicky, Peter J. Zwiers, Timara Kuiper, Elisabeth Schraml, Matthias Hackl, Grietje Molema
Supplementary Figure S1: Bioanalyzer Results obtained from PDAC compartments.(A) Human brain total RNA Was obtained from ThermoFisher nd diluted to 625pg/μl (left) and 312. 5pg/μl (right), Which was the expected range for total RNA Recovery from PDAC Compartments. Small RNA And ribosomal RNA Peaks are indicated. Total RNA Recovery from tumor (B), Stroma (C), And microvasculature (D). Recovery Was highest from 271, 100Μm 2 Tumor compartment compared to stroma and microvasculature. n/a, not assessible because of ow rRNA concentration.Supplementary Figure S1: Bioanalyzer Results obtained from PDAC compartments.(A) Human brain total RNA Was obtained from ThermoFisher nd diluted to 625pg/μl (left) and 312. 5pg/μl (right), Which was the expected range for total RNA Recovery from PDAC Compartments. Small RNA And ribosomal RNA Peaks are indicated. Total RNA Recovery from tumor (B), Stroma (C), And microvasculature (D). Recovery Was highest from 271, 100Μm 2 Tumor compartment compared to stroma and microvasculature. n/a, not assessible because of ow rRNA concentration.

Funding

Peter J. Zwiers and Timara Kuiper state that they have no conflicts of interest. Grietje Molema is co-founder and CScientific / Technology Officer of Vivomicx. Matthias Hackl is co-founder and CEO of TAmiRNA and holds patents related to the use of circulating microRNAs as disease biomarkers. Matthias Hackl, Susanna Skalicky and Elisabeth Schraml are employed by TAmiRNA GmbH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Peter J. Zwiers and Timara Kuiper state that they have no conflicts of interest. Grietje Molema is co-founder and CScientific / Technology Officer of Vivomicx. Matthias Hackl is co-founder and CEO of TAmiRNA and holds patents related to the use of circulating microRNAs as disease biomarkers. Matthias Hackl, Susanna Skalicky and Elisabeth Schraml are employed by TAmiRNA GmbH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

History

Exports